Bekker Petrus Form 4 March 19, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Bekker Petrus

2. Issuer Name and Ticker or Trading Symbol

Issuer

ChemoCentryx, Inc. [CCXI]

(Last)

(Middle)

3. Date of Earliest Transaction

Director _X__ Officer (give title 10% Owner

C/O CHEMOCENTRYX, INC., 850

(First)

(Street)

MAUDE AVENUE

03/15/2013

(Month/Day/Year)

below)

Other (specify

SVP of Medical & Clinical

(Check all applicable)

5. Relationship of Reporting Person(s) to

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting

Person

MOUNTAIN VIEW, CA 94043

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired (A) Transactioner Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
C			Code V	Amount	(D)	Price	(Ilisti. 5 and 4)			
Common Stock	03/15/2013		M	941	A	\$ 6	54,535	D		
Common Stock	03/15/2013		S <u>(1)</u>	941	D	\$ 14.0058 (2)	53,594	D		
Common Stock	03/15/2013		M	1,735	A	\$6	55,329	D		
Common Stock	03/15/2013		S <u>(1)</u>	1,735	D	\$ 14.1051 (3)	53,594	D		
	03/15/2013		M	2,103	A	\$6	55,697	D		

Common
Stock

Diock							
Common Stock	03/15/2013	S <u>(1)</u>	2,103	D	\$ 14.0771 (4)	53,594	D
Common Stock	03/15/2013	M	1,992	A	\$ 6	55,586	D
Common Stock	03/15/2013	S <u>(1)</u>	1,992	D	\$ 14.0471 (5)	53,594	D
Common Stock	03/15/2013	M	485	A	\$ 6	54,079	D
Common Stock	03/15/2013	S <u>(1)</u>	485	D	\$ 14	53,594	D
Common Stock	03/15/2013	M	1,633	A	\$ 6	55,227	D
Common Stock	03/15/2013	S <u>(1)</u>	1,633	D	\$ 14.0387 (6)	53,594	D
Common Stock	03/18/2013	M	2,500	A	\$ 0.6	56,094	D
Common Stock	03/18/2013	M	2,500	A	\$ 6	58,594	D
Common Stock	03/18/2013	S <u>(1)</u>	5,000	D	\$ 13.6111 (7)	53,594	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

 $\label{thm:convergence} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (e.g., puts, calls, warrants, options, convertible securities) \end{tabular}$

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exer	cisable and	7. Title and A	Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	onof Derivative	Expiration D	ate	Underlying S	Securities
Security	or Exercise		any	Code	Securities	(Month/Day/	Year)	(Instr. 3 and	4)
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired				
	Derivative				(A) or				
	Security				Disposed of				
	•				(D)				
					(Instr. 3, 4,				
					and 5)				
					,				
				Code V	(A) (D)	Date	Expiration	Title	Amount
						Exercisable	Date		or

								Number of Shares
Employee Stock Option (right to buy)	\$6	03/15/2013	M	5,105	(8)	09/10/2018	Common Stock	5,105
Employee Stock Option (right to buy)	\$ 6	03/15/2013	M	3,784	<u>(8)</u>	02/17/2019	Common Stock	3,784
Employee Stock Option (right to buy)	\$ 0.6	03/18/2013	M	2,500	<u>(8)</u>	05/05/2015	Common Stock	2,500
Employee Stock Option (right to buy)	\$ 6	03/18/2013	M	2,500	(8)	02/17/2019	Common Stock	2,500

Reporting Owners

Reporting Owner Name / Address			Relationships	
	Director	100/ Orrman	Officer	(

ector 10% Owner Officer Other

Bekker Petrus

C/O CHEMOCENTRYX, INC.
850 MAUDE AVENUE
SVP of Medical & Clinical

MOUNTAIN VIEW, CA 94043

Signatures

/s/ Susan M. Kanaya, as
Attorney-in-Fact
03/19/2013

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- (2) Reflects the weighted average sale price of the shares sold. 915 shares were sold at \$14.00 per share and 26 shares were sold at \$14.21 per share.

Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$14.00 to \$14.2650 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

Reporting Owners 3

Edgar Filing: Bekker Petrus - Form 4

- Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$14.00 to \$14.26 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$14.00 to (5) \$14.22 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- (6) Reflects the weighted average sale price of the shares sold. 1,346 shares were sold at \$14.00 per share and 287 shares were sold at \$14.22 per share.
- Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$13.50 to (7) \$13.75 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- (8) As of March 15, 2013 and prior to this transaction, the option fully vested.
- (9) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.